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NEW POTENTIAL DIAGNOSTIC METHODS FOR IDENTIFYING 
ANTICOAGULANT RODENTICIDE POISONING IN DOGS AND OTHER 
NONTARGET ANIMALS 
MICHAELE. MOUNT, Department of Clinical Pathology, School of Veterinary Medicine, University of 
California. Davis, California 95616. 
Analyti cal methods for anticoagulants are complex and encumbered with highly sophisticated 
instrumentation for determination of anticoagulant concentrations. This greatly limits the applicati on 
of anticoagulant measurement in biological samples as a diagnostic criteria to determine anticoagulant 
rodenticide poisoning . In the field of veterinary medicine, clinical laboratory measurements of the 
coagulation status in viable patients have been used historical ly as the means to make a diagnosis of 
anticoagulant poisoning. Nontarget animals (companion animals, e.g., dogs and cats ; livestock; or wild-
life), which are found dead in the context of an anticoagulant applicati on area, are a tremendous diag-
nostic challenge in spite of postmortem evidence of a hemorrhagic diathesis colllllon to death from such 
poisons. The recent understanding in the veterinary field (Mount and Feldman lgs3 , Mount et al . 1986) 
of the short versus long-acting anticoagulants has created a diagnostic dilerrma in relation of vitamin 
K1 therapy. It is therefore evident that analytical assays which possess high specificity , sensitivity, 
and economic feasibility are needed to better clarify these issues. 
Assays which possess those features are illlllunoassays. These have been applied to hormones and 
steroids which are found at very low concentrations in biological fluids. They have also found applica-
tion in drug monitoring and drugs-of-abuse identification in the medical field. The goal of this paper 
is to give an understanding as to how illlllunoassays are developed and how applied to anticoagulants. The 
development of such systems is timely and costly, but, once established , the cost per assay is minimal 
and their applicability is adaptable to most laboratory settings. The enzyme-linked immunosorbent assay 
(ELISA) is the immunoassay to be discussed. Using this system, assays can be run within an 8-hour day 
and sensitivity is in the ng/ml range, which is parts per billion (ppb) of biological material. 
The primary goal in developing an immunoassay is to produce antibodies in a 1 iving animal which 
recognizes the substance of interest. When people are vaccinated with an infectious agent to protect 
them from a specific disease , they are injected with proteins from a bacteria or virus. These materials 
are antigenic, allowing their bodies ' immune systems to be activated so as to process these foreign pro-
teins, resulting in clones of lymphocytes which produce antibodies capable of recognizing these newly 
introduced foreign proteins. Proteins are large molecular weight complexes (greater than ~ 40,000 
g/mole). Steroids, therapeutic drugs, as well as anticoagulants, are low molecular weight compounds 
(less than • 1000 g/mole) and are not antigenic. However, if these low molecular compounds are covalent-
ly coupled to proteins , the{ are made antigenic since antibodies produced against the coupled proteins 
will recognize these low mo ecular compounds when present in a solution uncoupled to protein. Thus 
these low molecular weight compounds can be defined as haptens; that is, by themselves these compounds 
will induce antibody production. But, when coupled to proteins, antibodies are produced which recognize 
the low molecular weight compounds when present in a solution containing the antibodies . 
In order to produce antibodies against anticoagulants, which can be referred to as haptens, they 
must be coupled to protein. Therefore, the first objective in the development of an illlllunoassay is to 
covalently couple the anticoagulant to a protein. To do this, the anticoagulant (hapten) must have 
chemical groups allowing for direct coupling to protein or allowing for attachment of a chemical bridge 
which introduces a functional group allowing for covalent linkage to protein. This is su11111arized in 
Figure l. The resulting product is referred to as the il!V1lunogen and used to vaccinate rabbits. The 
Figure 1. Basic steps required to convert a small 
molecular weight compound (Hapten) into an anti-
genic derivative. The bridge represents a chemi-
cal unit which is capable of covalently binding to 
the hapten so that the free end of the bridge con-
tains a functional group which is able to cova-
lently link to protein. Thus the HAPTEN is 
functionalized by linkage with the BRIDGE allowing 
for covalent binding with the PROTEIN. The pro-
tein-bound hapten is now antigenic. 
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site of coupling is important in order to maintain high specificity of antibodies to the anticoagulant 
of interest. Figure 2 demonstrates the two basic chemical structures of anticoagulants used in the field 
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Figure 2. All coumarin anticoagulants have the 4-hydroxy-coumarin nucleus 
and all indandione anticoagulants have the indandione nucleus. The "R" 
groups differ between the differing anticoagulants. 
today. The --R-group is the portion of the molecule which differentiates one coumarin (or indandione) 
from the other. Thus the goal of our work has been to couple via the coumarin or indandione nucleus 
thus exposing the --R group for antibody recognition. 
Antibodies raised in rabbits following several months of inrnunogen vaccinations, are collected and 
applied to the ELISA. A competitive ELISA has been developed for diphacinone and is outlined in Figure 3. 
Figure 3. The competitive enzyme-linked 
immunosorbent assay (ELISA) is illustrated. 
1) Antibody specific for the anticoagulant is 
adsorbed on to a solid support of a microtiter 
plate. 2) Samples, standards, and control 
reagents are added which occupy antibody 
binding sites depending on the amount of anti-
coagulant in those samples. 3) The enzyme-
conjugate of anticoagulant covalently bound to 
enzyme is added and more or less binds to the 
remaining available antibody binding sites 
depending on the amount of anticoagulant in 
Step 2. 4) Substrate is added which is con-
verted to a colored product dependent on the 
amount of enzyme present. Thus an accurate 
measure of the amount of anticoagulant and 
specificity for an anticoagulant can be 
determined. 
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COMPETITIVE ELISA 
The anticoagulant is coupled to the enzyme used in the assay . Antibody is a adsorbed onto a solid 
surface (Step 1) . Samples which may or may not contain the anticoagulant (the hapten) and analytical 
standard concentrations of anticoagulant which are added to the solid surface will result in the "hapten" 
occupying the avai lable antibody binding sites (Step 2). Thus when the anticoagulant-coupled-to-enzyme 
is added, more or less will occupy the antibody binding sites , depending upon how much anticoagulant was 
present in the sample or standard (Step 3). Following this, the substrate is added (Step 4) and allowed 
to develop, producing a color which can be measured with a spectrophotometer. The result is that a 
standard curve is generated which allows for accurate determination of the anticoagulant (hapten) in the 
biological sample. 
Currently, diphacinone is readily detected in sera of dogs exposed to the anticoagulant diphacinone. 
Chlorophacinone, which is identical to diphacinone except for one chlorine on the --R group, does cross-
react with the antibody, but it requires approximately 10 times the concentration of chlorophacinone to 
give the same effect as diphacinone. Sensitivity of the assay is 1 ppb. Since this compound is a long-
acting anticoagulant, dogs or cats presented to clinicians with a coagulopathy syndrome and responsive 
to vitamin K1 , can now easily be positively identified as poisoned with diphacinone. This allows clini-
cians to be aware of potential relapse of clinical signs if taken off of vitamin K1 therapy too early. 
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Currently a coupling method has been developed allowing for covalent linkage of the coumarin 
nucleus to protein. Warfarin, brodifacoum, and bromadiolone are soon to be tested for antibody produc-
tion. 
In conclusion, the application of ELISA to anticoagulant analysis offers tremendous advantages over 
conventional approaches. The diphacinone ELISA allows quick, sensitive analysis of sera and urines of 
animals thought exposed to diphacinone. Once identified, therapeutic recolllllendations can be assuredly 
made. The recent successful coupling of warfarin to protein opens the way to couple all coumarin anti-
coagulants with anticipation of being able to raise antibodies which are highly specific for each indi-
vidual coumarin anticoagulant. With antibody in hand, ELISA development would follow, leading to ra~id 
identification of the coumarin anticoagulant responsible for poisoning. Technological developments are 
currently available to perform rapid qualitative assays within 5 minutes using specially designed field 
kits. Such a kit for anticoagulants (once developed) would offer a revolutionary change in anticoagu-
lant analysis and provide tremendous advantages to the veterinarian as well as to researchers and com-
mercial operators to perform field monitoring. 
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